Topical 5‐fluorouracil in dermatologic disease

Prince, Garrett; Cameron, Michael C.; Fathi, Ramin; Alkousakis, Theodore

doi:10.1111/ijd.14106

Cited by 40 publications

(34 citation statements)

References 41 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When entering the cell, 5-FU inhibits thymidylate synthase, thereby blocking DNA synthesis. 1 , 3 , 4 This disruption preferentially targets rapidly proliferating cells. 3 , 4 Patients typically report brisk dermatitis, which includes pain, pruritus, erythema, irritation, erosion, crusting, and eczematous reaction.…”

Section: Discussionmentioning

confidence: 99%

“…1 , 3 , 4 This disruption preferentially targets rapidly proliferating cells. 3 , 4 Patients typically report brisk dermatitis, which includes pain, pruritus, erythema, irritation, erosion, crusting, and eczematous reaction. 5 Rare side effects include temporary hair loss, allergic contact dermatitis, wound infections, erysipelas, ulcers, neutropenia, and angioedema.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorouracil cream induced scarring alopecia after topical treatment of squamous cell carcinoma in situ

2021

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Fluorouracil cream induced scarring alopecia after topical treatment of squamous cell carcinoma in situ

2021

View full text Add to dashboard Cite

“…A number have achieved moderate success in the treatment of AK, such as topical 5-FU, imiquimod, ingenol mebutate, and diclofenac, which are all FDA approved for this indication (95). With regards to cSCC, topical 5-FU is also commonly used (96). Additionally, early randomized controlled trials show a high degree of clinical benefit from topical imiquimod in the context of cSCC, with approximately a 70% complete response rate (97,98).…”

Section: Intra-lesional and Topical Therapiesmentioning

confidence: 99%

Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient

et al. 2021

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide, with ever increasing incidence and mortality. While most patients can be treated successfully with surgical excision, cryotherapy, or radiation therapy, there exist a subset of patients with aggressive cSCC who lack adequate therapies. Among these patients are solid organ transplant recipients who due to their immunosuppression, develop cSCC at a dramatically increased rate compared to the normal population. The enhanced ability of the tumor to effectively undergo immune escape in these patients leads to more aggressive tumors with a propensity to recur and metastasize. Herein, we present a case of aggressive, multi-focal cSCC in a double organ transplant recipient to frame our discussion and current understanding of the immunobiology of cSCC. We consider factors that contribute to the significantly increased incidence of cSCC in the context of immunosuppression in this patient population. Finally, we briefly review current literature describing experience with localized therapies for cSCC and present a strong argument and rationale for consideration of an IL-2 based intra-lesional treatment strategy for cSCC, particularly in this immunosuppressed patient population.

show abstract

“…Human skin provides the most comfortably accessible route of drug administration. Topical administration is the route of choice for cutaneous pathologies like atopic dermatitis since it rarely presents systemic adverse effects when compared to other routes of drug administration [ 1 ]. The stratum corneum of the skin, composed of flat dead cells encompassing high keratin filaments surrounded by a lipophilic matrix consisting of keratin, ceramides, cholesterol, cholesterol esters, and various other fatty acids, provides a natural physical barrier against particle penetration [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus-Loaded Solid Lipid Nanoparticle Gel: Formulation Development and In Vitro Assessment for Topical Applications

Khan

Shah

Mohaini

et al. 2022

Gels

View full text Add to dashboard Cite

The currently available topical formulations of tacrolimus have minimal and variable absorption, elevated mean disposition half-life, and skin irritation effects resulting in patient noncompliance. In our study, we fabricated tacrolimus-loaded solid lipid nanoparticles (SLNs) that were converted into a gel for improved topical applications. The SLNs were prepared using a solvent evaporation method and characterized for their physicochemical properties. The particle size of the SLNs was in the range of 439 nm to 669 nm with a PDI of ≤0.4, indicating a monodispersed system. The Zeta potential of uncoated SLNs (F1–F5) ranged from −25.80 to −15.40 mV. Those values reverted to positive values for chitosan-decorated formulation (F6). The drug content and entrapment efficiency ranged between 0.86 ± 0.03 and 0.91 ± 0.03 mg/mL and 68.95 ± 0.03 and 83.68 ± 0.04%, respectively. The pH values of 5.45 to 5.53 depict their compatibility for skin application. The surface tension of the SLNs decreased with increasing surfactant concentration that could increase the adherence of the SLNs to the skin. The release of drug from gel formulations was significantly retarded in comparison to their corresponding SLN counterparts (p ≤ 0.05). Both SLNs and their corresponding gel achieved the same level of drug permeation, but the retention of the drug was significantly improved with the conversion of SLNs into their corresponding gel formulation (p ≤ 0.05) due to its higher bioadhesive properties.

show abstract

Topical 5‐fluorouracil in dermatologic disease

Cited by 40 publications

References 41 publications

Fluorouracil cream induced scarring alopecia after topical treatment of squamous cell carcinoma in situ

Fluorouracil cream induced scarring alopecia after topical treatment of squamous cell carcinoma in situ

Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient

Tacrolimus-Loaded Solid Lipid Nanoparticle Gel: Formulation Development and In Vitro Assessment for Topical Applications

Contact Info

Product

Resources

About